eligibility_summary
Adults 18–70 with newly diagnosed WHO grade 4 GBM, KPS ≥70, Survivin+ tumor, life expectancy ≥14 wks, adequate labs, consenting to contraception and to receive only RT, temozolomide, and PERCELLVAC-Sur. Exclude: residual >1 cm on early post-op MRI, 5-ALA use, incomplete/late chemoradiation, pre-treatment progression, drug allergies, pregnancy/lactation, high-dose steroids/immunosuppression, active infection, major comorbidities/autoimmune disease, viral seropositivity, other cancers, MRI inability, recent trials, or investigator concern.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
Interventions and mechanisms: 1) Survivin-loaded dendritic cell (DC) injection—an autologous cellular immunotherapy/therapeutic cancer vaccine—administered intradermally and intravenously (3 doses, 1×10^7–3×10^7 DCs). Mechanism: ex vivo–prepared DCs present survivin peptides to prime/expand tumor‑specific CD8+ and CD4+ T cells, promoting cytotoxic killing of survivin‑positive GBM cells and overcoming immune tolerance. 2) Standard temozolomide chemoradiation—an oral alkylating agent causing DNA damage/cytotoxicity. Targets: dendritic cells, T‑cell activation and antigen presentation (MHC I/II) pathways, and tumor cells expressing survivin/BIRC5 (IAP, anti‑apoptosis pathway).